RE:AstraZeneca posts ADC wins at SABCS in breast cancerDecember 09, 2022 - Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an objective response rate of 32% and a manageable safety profile in patients with metastatic TNBC in TROPION-PanTumor01 phase 1 trial.
Datopotamab deruxtecan plus durvalumab (Astrazeneca's PD-1 checkpoint inhibitor) results dmonstrated an objective response rate of 73.6% in first-line treatment of patients with metastatic TNBC in BEGONIA phase 1b/2 trial
Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo
Enhertu (trastuzumab deruxtecan), is a HER2-directed ADC, AstraZeneca and Daiichi Sankyo to treat HER2-positive and HER2-low metastatic breast cancer.